Abcodia, VolitionRx Collaborate on Nucleosome-based Dx for Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abcodia today said that it will collaborate with Singapore-based VolitionRx on developing biomarker-based tests for a variety of cancers.

The London-based firm said that the partnership will discover and develop diagnostic tests for lung, colorectal, and pancreatic cancer using VolitionRx's nucleosome technology. Abcodia said that it will work with VolitonRx on designing the program and identifying cohort samples from its large prospective serum biobank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.